<DOC>
	<DOC>NCT01579006</DOC>
	<brief_summary>This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to) treatment with non-biological DMARDs or with one biological agent. Data will be collected from each eligible patient initiated on RoActemra/Actemra treatment by their treating physician according to approved label for 6 months from start of treatment.</brief_summary>
	<brief_title>Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis Inadequate response (or intolerant) to nonbiological DMARDs or one biologic agent Patients initiating treatment with RoActemra/Actemra on their physician's decision (in accordance with the local label), including patients who started treatment with RoActemra/Actemra in the 8 weeks prior to the enrolment visit RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use Enrolled in an ongoing clinical trial and/or treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>